Rapport Therapeutics, Inc. Common Stock (NASDAQ: RAPP) is a Healthcare company (Biotechnology) with a market capitalization of $1.1B. The Maz Rating grades it against the other companies in its sector.
Rapport Therapeutics, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $23.76, Rapport Therapeutics, Inc. Common Stock trades at 56.9x sales and 2.9x book value. Over the last twelve months it generated about $20M of revenue and a net loss of $152M. It runs an operating margin of -838.1% and a net margin of -752.4%. It shows return on equity of -34.0%, return on invested capital of -41.8% and a free cash flow yield of -10.6%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 20.07. Over the past 52 weeks the share price ranged from $22.06 to $52.93, with a beta of 1.03.
Rapport Therapeutics, Inc. Common Stock does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 8 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Rapport Therapeutics, Inc. Common Stock (RAPP) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 23.5% / 30% · Interest income / Revenue 385100000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 23.5% / 33% · Receivables / Mkt Cap (36m) 0.01% / 49% · Interest income / Revenue 385100000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 23.5% / 33.33% · Receivables / Mkt Cap (24m) 0.01% / 33.33% · Interest income / Revenue 385100000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.90% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 95.3% / 33.33% · Receivables / Avg Assets (4Q) 0.03% / 33.33% · Interest income / Revenue 385100000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 94.4% / 33.33% · (Cash+Recv) / Total Assets 94.4% / 33.33% · Interest income / Revenue 385100000.0% / 5% | Fail |
No. As of September 2026, Rapport Therapeutics, Inc. Common Stock (RAPP) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Rapport Therapeutics, Inc. Common Stock is over the AAOIFI limit on Interest income / Revenue.
About 385100000.0% of each dividend: Rapport Therapeutics, Inc. Common Stock's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.